Printer-friendly versionPrinter-friendly version

Hepatitis B vaccination: safety issues

Geneva, Switzerland, March 13-14, 2003

Thursday, March 13, 2003

Session 1 Opening and objectives

Chair: Johannes Hallauer and Daniel Lavanchy
09.00 - 09.30

 

  • Welcome
  • Introduction of the participants
  • Objectives of the meeting:
    1. To review potential adverse events following hepatitis B vaccination.
    2. To update the points of view regarding safety issues and describe new developments.
    3. To describe the impact of safety issues in an international perspective.
    4. To discuss communication strategies to counter vaccination scares.
  • Review of the meeting programme
  • Safety issues - Pre-meeting document 145 Kb (.pdf) 

Session 2 Adverse events following hepatitis B immunisation

Chair: Johannes Hallauer and Daniel Lavanchy

09.30 - 10.05
Multiple sclerosis: state of the art
Philippe Duclos (Geneva, Switzerland)

10.05 - 10.40
Thiomersal-related changes in vaccination recommendations and hepatitis B vaccine coverage among United States children  350 Kb (.ppt)
Hal Margolis (Atlanta, USA)

10.40 - 11.00
Coffee break

11.00 - 11.35
Aluminium-containing vaccines and macrophagal myofasciitis (MMF): an update
Claire-Anne Siegrist (Geneva, Switzerland)

11.35 - 12.00
Infant hepatitis B vaccination and childhood leukaemia 87 Kb (.ppt)
Hal Margolis (Atlanta, USA)

12.00 - 12.35
Vaccination and autoimmune diseases: what is the risk?
Paul-Henri Lambert (Geneva, Switzerland)

12.35 - 14.00
Lunch

Session 3A Impact of safety issues and international points of view

Chair: Peter Grob and Wolfgang Jilg

14.00 - 14.25
Impact of safety issues in France  87 Kb (.ppt)
Nicole Guérin (Antony, France)

14.25 - 14.50
Impact of safety issues in Germany  644 Kb (.ppt)
Johannes Hallauer (Berlin, Germany)

14.50 - 15.10
Coffee break

15.10 - 15.35
Impact of safety issues in Scotland  1,386 Kb (.ppt) 
Claire Bramley (Glasgow, United Kingdom)

15.35 - 16.00
New communication issues around immunisation 1,090 Kb (.ppt)
Heidi Larson (New York, USA)

16.00
Close of the day and summary by the chairs

Conference dinner

Friday, March 14, 2003

Session 3B Impact of safety issues and international points of view

Chair: Nedret Emiroglu and André Meheus

09.00 - 09.25
Impact of safety issues in Israel 96 Kb (.ppt)
Daniel Shouval (Jerusalem, Israel)

09.25 - 09.55
International impact of vaccine safety concerns 33 Kb (.ppt)
Mark Kane (Seattle, USA)

09.55 - 10.25
Impact of litigation issues on hepatitis B vaccination 2,513 Kb (.pdf)
Robert Pless (Ottawa, Canada)

10.25 - 10.40
Coffee break

Session 4 Communication

ChairMark Kane and Daniel Shouval

10.40 - 11.10
The Global Advisory Committee on Vaccine Safety (GACVS) and its communication strategy  214 Kb (.ppt)
Philippe Duclos (Geneva, Switzerland)

11.10 - 11.40
The role of the industry   61Kb (.ppt)
Luc Hessel (Lyon, France), Hugues Bogaerts (Rixensart, Belgium)

11.40 - 12.10
The Brighton Collaboration: comparability of vaccine safety data 419 Kb (.ppt)
Jan Bonhöffer (Basel, Switzerland)

12.10 - 12.30
The Immunization Action Coalition (IAC) 2,409 Kb (.ppt) 
Deborah Wexler (Saint Paul, USA)

12.30 - 13.00
Countering the anti-vaccination movement and vaccination scares - Working with the media 4,286 Kb (.ppt)
Robert Aston (Horwich, United Kingdom)

13.00 - 14.30
Lunch

Session 5 Conclusions of the meeting

Chair: Selim Badur and Hal Margolis

14.30 - 16.00
Presentation of the VHPB meeting conclusions, including discussion
Guido François (Antwerpen, Belgium)

16.00
Close of the meeting

Tags: